# Elara initiates coverage on Alkem, Eris, IPCA and Mankind. Check ratings and targets — retained record

> Retained news record from news:india-et-markets.

Canonical: https://highsignal.app/data/records/560ef6f1a90d5c5c

[← sources](https://highsignal.app/data)


source: [news](https://highsignal.app/data/news) (news:india-et-markets)  published 2026-08-28 07:58 ingested 2026-08-28 14:43

[original source ↗](https://economictimes.indiatimes.com/markets/stocks/news/elara-initiates-coverage-on-alkem-eris-ipca-and-mankind-check-ratings-and-targets/articleshow/133586795.cms)

## retained text



```
According to Elara, Alkem offers the strongest potential for margin recovery, while Eris and Mankind could benefit from portfolio expansion, acquisition synergies and deleveraging. On IPCA, Elara noted that the stock's 30% rally over the past three months has already priced in much of the expected margin recovery.
Alkem Laboratories
- Rating: Buy
- Target Price: Rs 6,533
- Upside: 23%
- CMP: INR 5,320
According to Elara, stabilisation in the US business, the launch of generic Jynarque and narrowing losses in the medical devices and biologics CDMO businesses could support margin improvement from the second half of FY27.
Eris Lifesciences
- Rating: Accumulate
- Target price: Rs 1,471
- Upside: 12%
- CMP: Rs 1,312
It expects revenue and EBITDA CAGRs of around 10% and 7%, respectively, over FY26-FY28, adding that acquisition integration, improving cash generation and debt reduction could support profitability and return ratios.
IPCA Laboratories
- Rating: Reduce
- Target price: Rs 2,043
- Upside: 4%
- CMP: Rs 1,960
However, the brokerage said synergies from the Unichem integration have not materialised to the extent initially expected. Following the stock's 30% rise over three months, Elara believes much of the anticipated operational improvement is already reflected in its valuation.
Mankind Pharma
- Rating: Accumulate
- Target price: Rs 2,616
- Upside: 8%
- CMP: Rs 2,418
According to Elara, benefits from the Bharat Serums and Vaccines (BSV) acquisition should begin emerging after a slower-than-expected integration. It expects revenue and EBITDA CAGRs of around 11% and 14%, respectively, over FY26-FY28.
The brokerage also estimates that strong cash generation could help Mankind repay its Rs 6,200 crore debt by the end of FY28, with lower finance costs supporting EPS growth.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
(What's moving Sensex and Nifty Track latest market news, stock tips, Budget 2025, Share Market on Budget 2025 and expert advice, on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds .)
Subscribe to ET Prime and read the Economic Times ePaper Online.and Sensex Today.
Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price
(What's moving Sensex and Nifty Track latest market news, stock tips, Budget 2025, Share Market on Budget 2025 and expert advice, on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds .)
Subscribe to ET Prime and read the Economic Times ePaper Online.and Sensex Today.
Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price
```



document fetched 2026-08-29 02:42